August 25, 2026 03:18 am (IST)
Follow us:
Emerging markets affect Dr Reddy's Laboratories' December quarter performance
Hyderabad, Feb 9 (IBNS) Dr Reddy's Laboratories Ltd announced its consolidated financial results on Tuesday for the quarter ended December 31, 2015, where it posted consolidated revenue of ₹39.7 billion, up 3 per cent from the same period in 2014, largely because the healthy performance in North America Generics (NAG), Europe and India were partially offset by emerging markets, which were impacted by unfavorable macro-economic conditions.
Revenues from the Global Generics segment for the reported quarter was ₹33.6 billion, up 7 per cent from the year-ago quarter, primarily driven by North America, Europe and India.
Revenues from the Pharmaceutical Services and Active Ingredients (PSAI) segment was ₹5.1 billion in the reported quarter, and declined by 17 per cent from the same quarter a year ago.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
Latest Headlines
Tata Power Renewables marks a major milestone with the commissioning of 190.5 MW FDRE project in Rajasthan. All details inside
Mon, Aug 24 2026
Samsung's big AI push in India: New Pune facility to power next-gen data centre cooling
Mon, Aug 24 2026
Best Indicators For Futures Trading
Mon, Aug 24 2026
China orders massive EV recall: Nearly 3 million Teslas among 4.3 million vehicles affected
Mon, Aug 24 2026
Yes Bank launches ‘YES Essence’ for women. How can you avail it?
Fri, Aug 21 2026
Aditya Birla Capital enters gold loans: What consumers should know
Fri, Aug 21 2026